| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥17.52B | +22.6% |
| Gross profit | ¥0.23B | — |
| Operating income | ¥0.12B | — |
| Net income | ¥0.09B | -7.0% |
| Gross margin | 1.3% | Net margin 0.5% |
| Revenue Q/Q | +5.0% | — |
The filing did not disclose a revenue breakdown for this period.
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥17.29B | 98.7% |
| R&D | ¥0.02B | 0.1% |
| SG&A | ¥0.12B | 0.7% |
| Tax & other | ¥0.03B | 0.2% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
光韵达 ・ 富瑞特装 ・ 拓尔思 ・ 永利股份 ・ 银信科技 ・ 洲明科技 ・ 金城医药 ・ 开尔新材 ・ 方直科技 ・ 上海新阳 ・ ST美晨 ・ 冠昊生物
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies